据悉，Moderna已经公布了其名为mRNA-4157的个体化癌症疫苗的中期数据，该疫苗联合默沙东PD-1疗法K药用于治疗黑色素瘤。今年6月，mRNA-4157联合帕博利珠 ...

据悉，Moderna已经公布了其名为mRNA-4157的个体化癌症疫苗的中期数据，该疫苗联合... 智通财经APP获悉，据报道，Moderna(MRNA.US) 计划最早于明年推出一种 ...

据悉，Moderna已经公布了其名为mRNA-4157的个体化癌症疫苗的中期数据，该疫苗联合默沙东(MRK.US)PD-1疗法K药(Keytruda，帕博利珠单抗)用于治疗黑色素瘤。

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

目前Moderna公司的肿瘤疫苗mRNA-4157已进入临床III期，公司预计其针对黑色素瘤的管线最早有望在2025年实现商业化，中信证券认为mRNA肿瘤疫苗凭借在 ...

目前Moderna公司的肿瘤疫苗mRNA-4157已进入临床III期，公司预计其针对黑色素瘤的管线最早有望在2025年实现商业化，我们认为mRNA肿瘤疫苗凭借在降低复发和远端转移方面更优且更稳定的疗效表现，有望成为mRNA疫苗领域的下一重磅单品并迅速打开市场。 mRNA肿瘤 ...

Moderna 和 BioNTech已成为mRNA PCV行业中的先行者，其各自的PCV产品mRNA-4157 (V940) 和Autogene cevumeran (BNT122) 均采用个性化肿瘤新抗原mRNA序列并利用纳米脂质 ...

Moderna MRNA shares ended the last trading ... reported encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT ...

Moderna is evaluating multiple candidates in late-stage studies — mRNA-1647 [cytomegalovirus (CMV) vaccine], mRNA-1010 (influenza vaccine), mRNA-4157/V940 [individualized neoantigen therapy (INT ...

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7 ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...